Articles

The vaccine is 66% effective overall in preventing moderate to severe COVID-19 28 days after vaccination.

J&J’s COVID-19 Vaccine Candidate Effective in Preventing Moderate to Severe COVID-19

The vaccine met the primary endpoint with a vaccine efficacy of 89.3% in its Phase III trial in the United Kingdom and a vaccine efficacy of 49% in HIV-positive participants and 60% in HIV-negative participants in a South African Phase IIb trial. 

Novavax Shares Data from UK and South Africa COVID-19 Vaccine Candidate Trials 

The company is recalling one lot of Cisatracurium Besylate Injection, USP 10mg per 5mL because of mislabeling.

Meitheal Pharmaceuticals Recalls Cisatracurium Besylate 

The dispute between the European Commission (EC) of the European Union and pharmaceutical company AstraZeneca continues.



Vaccine Supply Dispute Between EU and AstraZeneca Continues

Biotechnology company, Polyplus-transfection, has started construction of a new facility in France to meet growth in the cell and gene therapy market.

Polyplus-transfection Commences Build of New Facility

The European Medicines Agency (EMA) has issued the first safety update on a COVID-19 vaccine—Comirnaty (Pfizer/BioNTech vaccine).

EMA Publishes Vaccine Safety Update on Comirnaty

BIA has welcomed the announcement from the UK government that genomics expertise and capacity will be offered globally to help identify new variants of the virus that cause COVID-19.

Industry Welcomes UK’s Offer to Provide Genomics Expertise to Identify New COVID Variants

The launch of HiScreen Fibro PrismA, the company’s newest product for early mAb purification process development strengthens Cytiva’s new fiber-based Protein A platform.

Cytiva Advances Fiber Chromatography Technology with New Launch

Evozyne’s evolution-based protein design technology will be used to research and develop proteins that could be used in the next generation of gene therapies.

Takeda and Evozyne Enter into Gene Therapy Collaboration 

The new division will provide system solutions and individual machines and components.

News